STOCK TITAN

Universal Corporation (NYSE: UVV) swings to loss on weaker tobacco and ingredients margins

(Moderate)
(Neutral)
Form Type
10-Q

Rhea-AI Filing Summary

Universal Corporation reported a weak start to fiscal 2027. For the quarter ended June 30, 2026, sales and other operating revenues were $523.8 million, down 12% from $593.8 million. Operating income fell to $2.3 million from $33.8 million, and net results swung to a $5.0 million loss attributable to Universal, or $(0.20) per diluted share, versus earnings of $0.34 a year earlier. Gross margin contracted to 15.9% from 19.2%.

Tobacco Operations revenue declined 13% to $437.1 million, with operating income down sharply to $3.5 million from $35.7 million on lower volumes, weaker prices, and a less favorable product mix. Ingredients Operations revenue slipped 3% to $86.7 million and moved to a $0.7 million operating loss, pressured by consumer market headwinds, high fixed costs, and inventory write-downs.

Liquidity remains solid: cash and cash equivalents were $173.6 million, net debt was $1.01 billion, and net debt represented 42% of net capitalization, flat versus the prior year. The company had $635 million available under its committed revolving credit facility plus about $279 million of uncommitted lines, with no long-term debt maturities until fiscal 2031. The quarterly dividend was maintained at $0.83 per share, and 51,741 shares were repurchased for $2.7 million.

Positive

  • None.

Negative

  • Profitability deteriorated sharply: operating income fell 93% to $2.3 million, and results swung to a $5.0 million net loss (diluted EPS $(0.20)) from $8.5 million of net income (EPS $0.34) a year earlier, driven by weaker tobacco volumes/pricing and losses in Ingredients.

Filing Explained

The filing reports share awards with future settlement terms and $52.9 million of receivables sold during the quarter.

This Form 10-Q is Universal's unaudited quarterly report for the quarter ended June 30, 2026, and it reports the quarter as completed. The disclosed equity mechanics are awards rather than a completed common-stock sale: Universal granted 93,352 restricted stock units and 58,285 performance share units.

RSUs generally vest after three years and are paid in common shares, while PSUs vest after a three-year performance period and can pay from zero to 150% of the stated award. If settled in shares, these awards would increase the share count and could reduce existing holders' percentage ownership, but that effect depends on vesting, performance, and settlement.

At June 30, 2026, $275.1 million, or 24%, of tobacco inventory was uncommitted; the company said it expects this level to be within 20% or less during fiscal 2027. The company also sold $52.9 million of trade receivables during the quarter, recording $0.6 million of discounts; the transactions were described as nonrecourse true sales that remove the receivables after settlement.

The stock-repurchase authorization runs through November 15, 2026 and had $97.3 million remaining at June 30, 2026; that amount is capacity, not a commitment to repurchase the full balance.

Sales and other operating revenues $523.8 million Consolidated revenue for the three months ended June 30, 2026, versus $593.8 million in 2025
Operating income $2.3 million Consolidated operating income for the quarter ended June 30, 2026, down from $33.8 million
Net income (loss) attributable to Universal Corporation $(5.0) million Net loss attributable to the company for the three months ended June 30, 2026
Diluted earnings (loss) per share $(0.20) Diluted EPS for the quarter ended June 30, 2026, versus $0.34 a year earlier
Tobacco Operations revenue $437.1 million Tobacco Operations sales and other operating revenues for the three months ended June 30, 2026
Ingredients Operations revenue $86.7 million Ingredients Operations sales and other operating revenues for the same quarter
Net debt (non-GAAP) $1,013,818 (in thousands) Net debt as of June 30, 2026, after deducting cash and cash equivalents
Net Debt/Net Capitalization 42% Net debt as a percentage of net capitalization at June 30, 2026
cost-plus contracts financial
"The Company does have a small number of cost-plus contracts with certain customers."
accumulated other comprehensive loss financial
"The effective portion of the gain or loss on the derivative is recorded in accumulated other comprehensive loss"
Accumulated other comprehensive loss is the running negative total of certain gains and losses that companies record outside their regular profit-and-loss statement, such as changes in the value of some investments, pension adjustments, or currency translation effects. It matters to investors because it reduces shareholders’ equity and reveals economic swings that haven’t affected reported net income yet — like a side ledger showing pending ups and downs that could influence future cash flow or balance-sheet strength.
cash flow hedges financial
"Contracts related to tobacco purchases and crop input sales were designated and qualified as hedges of the future cash flows"
A cash flow hedge is an accounting label companies use when they enter financial contracts—like currency or interest-rate agreements—to protect expected future cash payments or receipts from unpredictable moves. For investors, it signals that the company is trying to smooth out future cash variability (think of locking in a price to avoid surprises), which can reduce reported profit swings but also means the company has exposure to derivative instruments and their associated risks.
Segment operating income financial
"The CODM currently evaluates the performance of the operating segments based on operating income after allocated overhead expenses, plus equity in the pretax earnings of unconsolidated affiliates (“Segment Operating Income”)."
Segment operating income is the profit a company earns from one specific part of its business after subtracting the costs of running that part but before interest, taxes and corporate-level items. For investors, it shows which divisions are actually generating operating profit and lets you compare the health and efficiency of different business “slices,” much like checking the cash a single store in a chain makes before company-wide overhead is applied.
net debt financial
"We consider the sum of notes payable and overdrafts, long-term debt..., less cash... to be our net debt."
Net debt is the total amount a company owes after subtracting the cash and assets it has that can be used to pay off that debt. It shows how much debt is truly a burden, helping investors understand if a company is financially healthy or heavily borrowed. Think of it like calculating how much money you owe after using your savings to pay part of it.
value-added tax credits financial
"the aggregate balance of recoverable tax credits held by the Company’s subsidiaries totaled approximately $80 million"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How did Universal Corporation (UVV) perform financially in the quarter ended June 30, 2026?

Universal Corporation reported sales of $523.8 million, down 12% year over year, and a net loss of $5.0 million attributable to the company. Diluted earnings per share were $(0.20), compared with $0.34 in the prior-year quarter, as margins and volumes weakened.

What were the results for UVV’s Tobacco Operations segment this quarter?

Tobacco Operations generated $437.1 million in sales and other operating revenues, a 13% decline from last year. Segment operating income dropped to $3.5 million from $35.7 million, reflecting a less favorable product mix, lower sales volumes, and reduced green tobacco prices.

How did the Ingredients Operations segment of UVV perform in the latest quarter?

Ingredients Operations posted $86.7 million in sales and other operating revenues, down 3% year over year, and an operating loss of $0.7 million. Results were affected by consumer market headwinds, high fixed costs at expanded facilities, and inventory write-downs of $1.4 million.

What is Universal Corporation’s (UVV) current debt and liquidity position?

As of June 30, 2026, UVV had net debt of $1,013,818 thousand and a net debt-to-net capitalization ratio of 42%. The company held $173.6 million in cash and cash equivalents and had $635 million available under its committed revolving credit facility, plus uncommitted lines.

Did UVV continue its dividend and share repurchase activities this quarter?

Yes. Universal Corporation declared dividends of $0.83 per common share for the quarter. It also repurchased 51,741 shares of common stock for approximately $2.7 million, leaving $97.3 million of capacity under its current $100 million share repurchase authorization through November 15, 2026.

What is happening with UVV’s tobacco inventory and uncommitted stock levels?

At June 30, 2026, tobacco inventories were $1,165.5 million, with uncommitted tobacco inventory at $275.1 million, about 24% of total tobacco inventory. Management expects uncommitted inventory to move toward its target range of 20% or less during fiscal 2027 as customer commitments finalize.

How leveraged is UVV and when does its long-term debt mature?

UVV’s total debt was $1,183,880 thousand at June 30, 2026, with net debt at 42% of net capitalization. The company reported compliance with all financial covenants and indicated it has no long-term debt maturities until fiscal year 2031, supporting balance-sheet flexibility.
FALSE2027Q10000102037--03-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureuvv:segments00001020372026-04-012026-06-3000001020372026-08-0300001020372025-04-012025-06-3000001020372026-06-3000001020372025-06-3000001020372026-03-310000102037us-gaap:SeriesAPreferredStockMember2025-06-300000102037us-gaap:SeriesAPreferredStockMember2026-03-310000102037us-gaap:SeriesAPreferredStockMember2026-06-300000102037us-gaap:CommonStockMember2025-06-300000102037us-gaap:CommonStockMember2026-03-310000102037us-gaap:CommonStockMember2026-06-3000001020372025-03-310000102037country:DEuvv:TobaccoOperationsMember2025-04-012025-06-300000102037uvv:TobaccoOperationsMember2025-04-012025-06-300000102037us-gaap:EmployeeSeveranceMember2025-04-012025-06-300000102037us-gaap:OtherRestructuringMember2025-04-012025-06-300000102037us-gaap:FacilityClosingMember2025-04-012025-06-300000102037us-gaap:ManufacturedProductOtherMemberuvv:TobaccoSalesMember2026-04-012026-06-300000102037us-gaap:ManufacturedProductOtherMemberuvv:TobaccoSalesMember2025-04-012025-06-300000102037us-gaap:ManufacturedProductOtherMemberuvv:FoodIngredientSalesMember2026-04-012026-06-300000102037us-gaap:ManufacturedProductOtherMemberuvv:FoodIngredientSalesMember2025-04-012025-06-300000102037us-gaap:ServiceOtherMember2026-04-012026-06-300000102037us-gaap:ServiceOtherMember2025-04-012025-06-300000102037us-gaap:ProductAndServiceOtherMember2026-04-012026-06-300000102037us-gaap:ProductAndServiceOtherMember2025-04-012025-06-300000102037uvv:AdvancestosuppliersMember2026-06-300000102037uvv:AdvancestosuppliersMember2025-06-300000102037uvv:AdvancestosuppliersMember2026-03-310000102037uvv:AdvancestosuppliersMember2026-04-012026-06-300000102037uvv:AdvancestosuppliersMember2025-04-012025-06-300000102037uvv:RecoverablevalueaddedtaxcreditsMember2026-06-300000102037uvv:RecoverablevalueaddedtaxcreditsMember2025-06-300000102037uvv:RecoverablevalueaddedtaxcreditsMember2026-03-310000102037srt:MinimumMemberus-gaap:CustomerRelationshipsMember2026-06-300000102037srt:MaximumMemberus-gaap:CustomerRelationshipsMember2026-06-300000102037us-gaap:CustomerRelationshipsMember2026-06-300000102037us-gaap:TradeNamesMember2026-06-300000102037us-gaap:DevelopedTechnologyRightsMember2026-06-300000102037us-gaap:NoncompeteAgreementsMember2026-06-300000102037us-gaap:OtherIntangibleAssetsMember2026-06-300000102037srt:MinimumMemberus-gaap:CustomerRelationshipsMember2025-06-300000102037srt:MaximumMemberus-gaap:CustomerRelationshipsMember2025-06-300000102037us-gaap:CustomerRelationshipsMember2025-06-300000102037us-gaap:TradeNamesMember2025-06-300000102037us-gaap:DevelopedTechnologyRightsMember2025-06-300000102037us-gaap:NoncompeteAgreementsMember2025-06-300000102037us-gaap:OtherIntangibleAssetsMember2025-06-300000102037srt:MinimumMemberus-gaap:CustomerRelationshipsMember2026-03-310000102037srt:MaximumMemberus-gaap:CustomerRelationshipsMember2026-03-310000102037us-gaap:CustomerRelationshipsMember2026-03-310000102037us-gaap:TradeNamesMember2026-03-310000102037us-gaap:DevelopedTechnologyRightsMember2026-03-310000102037us-gaap:NoncompeteAgreementsMember2026-03-310000102037us-gaap:OtherIntangibleAssetsMember2026-03-310000102037us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2026-06-300000102037us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-12-310000102037us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-04-012023-12-310000102037us-gaap:DesignatedAsHedgingInstrumentMemberuvv:TobaccopurchasesMemberus-gaap:ForeignExchangeContractMember2026-06-300000102037us-gaap:DesignatedAsHedgingInstrumentMemberuvv:TobaccopurchasesMemberus-gaap:ForeignExchangeContractMember2025-06-300000102037us-gaap:NondesignatedMemberuvv:ProcessingcostsMemberus-gaap:ForeignExchangeContractMember2026-06-300000102037us-gaap:NondesignatedMemberuvv:ProcessingcostsMemberus-gaap:ForeignExchangeContractMember2025-06-300000102037us-gaap:NondesignatedMemberuvv:OperatingCostsMemberus-gaap:ForeignExchangeContractMember2026-06-300000102037us-gaap:NondesignatedMemberuvv:OperatingCostsMemberus-gaap:ForeignExchangeContractMember2025-06-300000102037us-gaap:ForeignExchangeContractMember2026-06-300000102037us-gaap:ForeignExchangeContractMember2025-06-300000102037us-gaap:ForeignExchangeForwardMember2026-06-300000102037us-gaap:ForeignExchangeForwardMember2025-06-300000102037us-gaap:ForeignExchangeForwardMember2026-03-310000102037us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2026-04-012026-06-300000102037us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2025-04-012025-06-300000102037us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2026-04-012026-06-300000102037us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2025-04-012025-06-300000102037us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2026-04-012026-06-300000102037us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2025-04-012025-06-300000102037us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2026-04-012026-06-300000102037us-gaap:InterestRateContractMember2026-06-300000102037us-gaap:InterestRateContractMember2025-06-300000102037us-gaap:InterestRateContractMember2026-03-310000102037us-gaap:ForeignExchangeContractMember2026-03-310000102037us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2026-06-300000102037us-gaap:FairValueInputsLevel1Member2026-06-300000102037us-gaap:FairValueInputsLevel2Member2026-06-300000102037us-gaap:FairValueInputsLevel3Member2026-06-300000102037us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-06-300000102037us-gaap:FairValueInputsLevel1Member2025-06-300000102037us-gaap:FairValueInputsLevel2Member2025-06-300000102037us-gaap:FairValueInputsLevel3Member2025-06-300000102037us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2026-03-310000102037us-gaap:FairValueInputsLevel1Member2026-03-310000102037us-gaap:FairValueInputsLevel2Member2026-03-310000102037us-gaap:FairValueInputsLevel3Member2026-03-310000102037us-gaap:EstimateOfFairValueFairValueDisclosureMember2026-06-300000102037us-gaap:EstimateOfFairValueFairValueDisclosureMember2025-06-300000102037us-gaap:EstimateOfFairValueFairValueDisclosureMember2026-03-310000102037us-gaap:CarryingReportedAmountFairValueDisclosureMember2026-06-300000102037us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-06-300000102037us-gaap:CarryingReportedAmountFairValueDisclosureMember2026-03-310000102037us-gaap:PensionPlansDefinedBenefitMember2026-04-012026-06-300000102037us-gaap:PensionPlansDefinedBenefitMember2025-04-012025-06-300000102037us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2026-04-012026-06-300000102037us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-04-012025-06-300000102037us-gaap:RestrictedStockUnitsRSUMember2026-04-012026-06-300000102037us-gaap:PerformanceSharesMember2026-04-012026-06-300000102037us-gaap:PerformanceSharesMembersrt:MinimumMember2026-04-012026-06-300000102037us-gaap:PerformanceSharesMembersrt:MaximumMember2026-04-012026-06-300000102037us-gaap:RestrictedStockUnitsRSUMembersrt:DirectorMember2026-04-012026-06-300000102037us-gaap:RestrictedStockUnitsRSUMember2025-04-012025-06-300000102037us-gaap:PerformanceSharesMember2025-04-012025-06-300000102037uvv:TobaccoOperationsMember2026-04-012026-06-300000102037uvv:IngredientsOperationsMember2026-04-012026-06-300000102037uvv:IngredientsOperationsMember2025-04-012025-06-300000102037uvv:ExcludingCorpOverheadMember2026-04-012026-06-300000102037uvv:ExcludingCorpOverheadMember2025-04-012025-06-300000102037uvv:TotalOperatingSegmentsMember2026-04-012026-06-300000102037uvv:TotalOperatingSegmentsMember2025-04-012025-06-300000102037uvv:TobaccoOperationsMember2026-06-300000102037uvv:TobaccoOperationsMember2025-06-300000102037uvv:TobaccoOperationsMember2026-03-310000102037uvv:IngredientsOperationsMember2026-06-300000102037uvv:IngredientsOperationsMember2025-06-300000102037uvv:IngredientsOperationsMember2026-03-310000102037us-gaap:AccumulatedTranslationAdjustmentMember2026-03-310000102037us-gaap:AccumulatedTranslationAdjustmentMember2025-03-310000102037us-gaap:AccumulatedTranslationAdjustmentMember2026-04-012026-06-300000102037us-gaap:AccumulatedTranslationAdjustmentMember2025-04-012025-06-300000102037us-gaap:AccumulatedTranslationAdjustmentMember2026-06-300000102037us-gaap:AccumulatedTranslationAdjustmentMember2025-06-300000102037us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-03-310000102037us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-03-310000102037us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-04-012026-06-300000102037us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-04-012025-06-300000102037us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-06-300000102037us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-06-300000102037us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-03-310000102037us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-03-310000102037us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-04-012026-06-300000102037us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-04-012025-06-300000102037us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-06-300000102037us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-06-300000102037us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-03-310000102037us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-03-310000102037us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-04-012026-06-300000102037us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-04-012025-06-300000102037us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-06-300000102037us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-06-300000102037us-gaap:ParentMember2026-03-310000102037us-gaap:NoncontrollingInterestMember2026-03-310000102037us-gaap:ParentMember2025-03-310000102037us-gaap:NoncontrollingInterestMember2025-03-310000102037us-gaap:ParentMember2026-04-012026-06-300000102037us-gaap:NoncontrollingInterestMember2026-04-012026-06-300000102037us-gaap:ParentMember2025-04-012025-06-300000102037us-gaap:NoncontrollingInterestMember2025-04-012025-06-300000102037us-gaap:ParentMember2026-06-300000102037us-gaap:NoncontrollingInterestMember2026-06-300000102037us-gaap:ParentMember2025-06-300000102037us-gaap:NoncontrollingInterestMember2025-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2026
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM ______________TO_______________

Commission File Number: 001-00652

UNIVERSAL CORPORATION
(Exact name of registrant as specified in its charter)
Virginia54-0414210
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
9201 Forest Hill Avenue,Richmond,Virginia23235
(Address of principal executive offices)(Zip Code)

804-359-9311
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each Exchange on which registered
Common Stock, no par valueUVVNew York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yesþ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large Accelerated FilerþAccelerated filer Non-accelerated filer
Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
As of August 3, 2026, the total number of shares of common stock outstanding was 24,899,257.



UNIVERSAL CORPORATION
FORM 10-Q
TABLE OF CONTENTS
Item No.Page
PART I - FINANCIAL INFORMATION
1.
Financial Statements
3
2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
24
3.
Quantitative and Qualitative Disclosures About Market Risk
31
4.
Controls and Procedures
31
PART II - OTHER INFORMATION
1.
Legal Proceedings
32
1A.
Risk Factors
32
2.
Unregistered Sales of Equity Securities and Use of Proceeds
32
5.
Other Information
32
6.
Exhibits
33
Signatures
34
2




PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

UNIVERSAL CORPORATION
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(in thousands, except share and per share data)
Three Months Ended June 30,
20262025
(Unaudited)
Sales and other operating revenues$523,779 $593,762 
Costs and expenses
Cost of goods sold440,691 479,635 
Selling, general and administrative expenses80,792 79,192 
Restructuring and impairment costs 1,122 
Operating income2,296 33,813 
Equity in pretax earnings (loss) of unconsolidated affiliates510 2,435 
Other non-operating income (expense)91 586 
Interest income741 647 
Interest expense16,507 17,777 
Income (loss) before income taxes and other items(12,869)19,704 
Income taxes(4,519)5,337 
Net income (loss)(8,350)14,367 
Less: net (income) loss attributable to noncontrolling interests in subsidiaries3,334 (5,870)
Net income (loss) attributable to Universal Corporation$(5,016)$8,497 
Earnings per share:
Basic
$(0.20)$0.34 
Diluted
$(0.20)$0.34 
Weighted average common shares outstanding:
Basic
25,081,430 24,999,570 
Diluted
25,081,430 25,131,857 
Total comprehensive income (loss), net of income taxes$(9,424)$23,102 
Less: comprehensive (income) loss attributable to noncontrolling interests3,424 (5,893)
Comprehensive income (loss) attributable to Universal Corporation$(6,000)$17,209 
Dividends declared per common share$0.83 $0.82 

See accompanying notes.

3


UNIVERSAL CORPORATION     
CONSOLIDATED BALANCE SHEETS
(in thousands of dollars, except share data)
June 30,June 30,March 31,
202620252026
(Unaudited)(Unaudited)
ASSETS
Current assets
Cash and cash equivalents$173,593 $178,435 $62,178 
Accounts receivable, net348,036 424,157 563,864 
Advances to suppliers, net102,880 79,154 177,222 
Accounts receivable—unconsolidated affiliates104,518 127,701 12,300 
Inventories—at lower of cost or net realizable value:
Tobacco1,165,542 1,219,769 832,360 
Other206,658 205,036 203,537 
Prepaid income taxes34,116 22,715 22,958 
Other current assets104,583 89,360 97,278 
Total current assets2,239,926 2,346,327 1,971,697 
Property, plant and equipment
Land26,414 26,266 26,249 
Buildings333,702 337,290 333,416 
Machinery and equipment768,886 739,899 759,654 
1,129,002 1,103,455 1,119,319 
Less accumulated depreciation(752,384)(728,180)(746,365)
376,618 375,275 372,954 
Other assets
Operating lease right-of-use assets35,134 38,428 37,272 
Goodwill, net172,679 213,864 172,695 
Other intangibles, net46,593 55,237 48,604 
Investments in unconsolidated affiliates81,243 87,988 82,287 
Deferred income taxes18,565 20,461 15,636 
Pension asset16,496 13,006 16,542 
Other noncurrent assets48,213 38,721 49,080 
418,923 467,705 422,116 
Total assets$3,035,467 $3,189,307 $2,766,767 

See accompanying notes.
4


UNIVERSAL CORPORATION     
CONSOLIDATED BALANCE SHEETS
(in thousands of dollars, except share data)

June 30,June 30,March 31,
202620252026
(Unaudited)(Unaudited)
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Notes payable and overdrafts$567,011 $621,275 $287,564 
Accounts payable90,976 119,803 90,139 
Accounts payable—unconsolidated affiliates255 76 510 
Customer advances and deposits3,531 4,557 3,376 
Accrued compensation25,079 22,577 33,234 
Income taxes payable12,946 15,528 17,643 
Current portion of operating lease liabilities10,471 11,233 11,172 
Accrued expenses and other current liabilities160,667 147,639 120,603 
Total current liabilities870,936 942,688 564,241 
Long-term debt616,869 618,057 616,727 
Pensions and other postretirement benefits35,434 36,307 35,471 
Long-term operating lease liabilities22,858 24,945 24,359 
Other long-term liabilities26,253 26,032 24,925 
Deferred income taxes40,223 41,689 39,920 
Total liabilities1,612,573 1,689,718 1,305,643 
Shareholders’ equity
Universal Corporation:
Preferred stock:
Series A Junior Participating Preferred Stock, no par value, 500,000 shares authorized, none issued or outstanding
   
Common stock, no par value, 100,000,000 shares authorized 24,938,259 shares issued and outstanding at June 30, 2026 (24,807,613 at June 30, 2025 and 24,923,496 at March 31, 2026)
353,899 355,498 351,523 
Retained earnings1,109,026 1,174,758 1,136,989 
Accumulated other comprehensive loss(74,096)(71,339)(73,112)
Total Universal Corporation shareholders' equity1,388,829 1,458,917 1,415,400 
Noncontrolling interests in subsidiaries34,065 40,672 45,724 
Total shareholders' equity1,422,894 1,499,589 1,461,124 
Total liabilities and shareholders' equity$3,035,467 $3,189,307 $2,766,767 

See accompanying notes.


5


UNIVERSAL CORPORATION     
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands of dollars)
Three Months Ended June 30,
20262025
(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)$(8,350)$14,367 
Adjustments to reconcile net income (loss) to net cash used by operating activities:
Depreciation and amortization12,760 13,582 
Net provision for losses (recoveries) on advances to suppliers1,752 52 
Inventory writedowns1,624 1,469 
Stock-based compensation expense5,378 7,575 
Foreign currency remeasurement (gain) loss, net2,821 (2,362)
Foreign currency exchange contracts1,250 (6,162)
Deferred income taxes(3,013)(3,259)
Equity in net loss (income) of unconsolidated affiliates, net of dividends(200)(1,943)
Restructuring and impairment costs 1,122 
Restructuring payments (2,669)
Other, net348 (43)
Changes in operating assets and liabilities, net:
Accounts and notes receivable194,398 169,177 
Inventories(338,573)(419,123)
Other assets(7,711)627 
Accounts payable2,763 16,678 
Accrued expenses and other current liabilities33,177 5,879 
Income taxes(15,790)(548)
Customer advances and deposits247 478 
Net cash used by operating activities(117,119)(205,103)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment(15,926)(12,053)
Proceeds from sale of property, plant and equipment281 143 
Net cash used by investing activities(15,645)(11,910)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of short-term debt, net278,220 165,861 
Dividends paid to noncontrolling interests(8,235)(7,203)
Repurchase of common stock(2,746) 
Dividends paid on common stock(20,437)(20,020)
Other(2,504)(4,016)
Net cash provided by financing activities244,298 134,622 
Effect of exchange rate changes on cash, restricted cash and cash equivalents(119)711 
Net increase (decrease) in cash, restricted cash and cash equivalents111,415 (81,680)
Cash, restricted cash and cash equivalents at beginning of year62,178 260,115 
Cash, restricted cash and cash equivalents at end of period$173,593 $178,435 

See accompanying notes.
6


UNIVERSAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1.   BASIS OF PRESENTATION
Universal Corporation, which together with its subsidiaries is referred to herein as “Universal” or the “Company,” is a global business-to-business agri-products supplier to consumer product manufacturers. The Company is the leading global leaf tobacco supplier and provides high-quality plant-based ingredients to food and beverage end markets. Because of the seasonal nature of the Company’s business, the results of operations for any fiscal quarter will not necessarily be indicative of results to be expected for other quarters or a full fiscal year. All adjustments necessary to state fairly the results for the period have been included and were of a normal recurring nature. This Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026.
Accounting Pronouncements to be Adopted in Future Years
In November 2024, the Financial Accounting Standards Board issued Accounting Standards Update No. 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40) - Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 requires additional disclosures about certain types of costs and expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and for interim periods beginning after December 15, 2027, although early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its consolidated financial statements.
NOTE 2.  RESTRUCTURING AND IMPAIRMENT COSTS
Universal regularly reviews its business for opportunities to realize efficiencies, reduce costs, and realign its operations in response to business changes. Restructuring and impairment costs are periodically incurred in connection with those activities.
Tobacco Operations
In fiscal year 2025, the Company began consolidating its European sheet tobacco operations into the Company's facility in the Netherlands, by initiating a wind-down of activities at its sheet facility in Germany. During the three months ended June 30, 2025, the Company recognized $1 million of impairment costs related to the consolidation of the sheet tobacco operations. The Company also incurred $0.1 million of termination and impairment costs in other areas of the Tobacco Operations segment in the three months ended June 30, 2025.
There were no restructuring and impairment costs recognized in the three months ended June 30, 2026.
A summary of the restructuring and impairment costs recorded for the three months ended June 30, 2025 follows:
Three Months Ended June 30,
(in thousands)2025
Restructuring costs:
  Employee termination benefits$122 
  Other 
    Total restructuring costs122 
Impairment costs:
  Property, plant and equipment1,000 
    Total impairment costs1,000 
      Total restructuring and impairment costs$1,122 
NOTE 3.  REVENUE FROM CONTRACTS WITH CUSTOMERS
The majority of the Company’s consolidated revenue consists of sales of processed leaf tobacco to customers. The Company also earns revenue from processing leaf tobacco owned by customers and from various other services provided to customers. Additionally, the Company has fruit and vegetable processing operations, as well as flavor and extract services that provide customers with a range of food ingredient products. Payment terms with customers vary depending on customer creditworthiness, product types, services provided, and other factors. Contract durations and payment terms for all revenue categories generally do not exceed one year. Therefore, the Company has applied a practical expedient to not adjust the transaction price for the effects of financing components, as the Company expects that the period from the time the revenue for a
7


transaction is recognized to the time the customer pays for the related good or service transferred will be one year or less. Below is a description of the major revenue-generating categories from contracts with customers.
Tobacco Sales
The majority of the Company’s business involves purchasing leaf tobacco from farmers in the regions where it is grown, processing and packing the tobacco in its factories, and then transferring ownership and control of the tobacco to customers. On a much smaller basis, the Company also sources processed tobacco from third-party suppliers for resale to customers. The contracts for tobacco sales with customers create a performance obligation to transfer tobacco to the customer. Transaction prices for the sale of tobacco are primarily based on negotiated fixed prices, but the Company does have a small number of cost-plus contracts with certain customers. Cost-plus arrangements provide the Company reimbursement of the cost to purchase and process the tobacco, plus a contractually agreed-upon profit margin. The Company utilizes the most likely amount methodology under the accounting guidance to recognize revenue for cost-plus arrangements with customers. Shipping and handling costs under tobacco sales contracts with customers are treated as fulfillment costs and included in the transaction price. Under agreements with certain customers, the Company will act as the importer of record, incurring various additional costs associated with the import activity, including tariffs, and applying for drawback of those costs when possible. When the agreement with the customer provides for the reimbursement of those fees, the reimbursement is included in the transaction price. Taxes assessed by government authorities on the sale of leaf tobacco products are excluded from the transaction price. At the point in time that the customer obtains control over the tobacco, which is typically aligned with physical shipment under the contractual terms with the customer, the Company completes its performance obligation and recognizes the revenue for the sale.
Ingredient Sales
The Company has diversified operations through acquisition of established companies that offer customers a wide range of both liquid and dehydrated fruit and vegetable ingredient products, flavors, and botanical extracts. These operations procure raw materials from domestic and international growers and suppliers and through a variety of processing steps including sorting, cleaning, pressing, mixing, extracting, and blending to manufacture finished goods utilized in both human and pet food. The contracts for food ingredients with customers create a performance obligation to transfer the manufactured finished goods to the customer. Transaction prices for the sale of food ingredients are primarily based on negotiated fixed prices, but the Company does have cost-plus contracts with certain customers. The Company utilizes the most likely amount methodology under the accounting guidance to recognize revenue for cost-plus arrangements with customers. At the point in time that the customer obtains control over the finished product, which is typically aligned with physical shipment under the contractual terms with the customer, the Company completes its performance obligation and recognizes the revenue for the sale.
Processing Revenue
Processing and packing of customer-owned tobacco and ingredients is a short-duration process. Processing charges are primarily based on negotiated fixed prices per unit of weight processed. Under normal operating conditions, customer-owned raw materials that are placed into the production line exits as processed and packed product and is then later transported to customer-designated transfer locations. The revenue for these services is recognized when the performance obligation is satisfied, which is generally when processing is completed. The Company’s operating history and contract analyses indicate that customer requirements for processed tobacco and food ingredients products are consistently met upon completion of processing.
Other Sales and Revenue from Contracts with Customers
From time to time, the Company enters into various arrangements with customers to provide other value-added services that may include blending, chemical and physical testing of products, storage, logistics, sorting, and tobacco cutting services for select manufacturers. These other arrangements and operations are a much smaller portion of the Company’s business, and are separate and distinct contractual agreements from the Company’s tobacco and food ingredients sales or third-party processing arrangements with customers. The transaction prices and timing of revenue recognition of these items are determined by the specifics of each contract.
8


Disaggregation of Revenue from Contracts with Customers
The following table disaggregates the Company’s revenue by significant revenue-generating category:
Three Months Ended June 30,
(in thousands of dollars)20262025
Tobacco sales$395,727 $457,873 
Ingredient sales82,252 84,943 
Processing revenue31,449 30,768 
Other sales and revenue from contracts with customers10,829 19,057 
   Total revenue from contracts with customers520,257 592,641 
Other operating sales and revenues3,522 1,121 
   Consolidated sales and other operating revenues$523,779 $593,762 
Other operating sales and revenue consists principally of interest on advances to tobacco suppliers and dividend income from unconsolidated affiliates.
NOTE 4. OTHER CONTINGENT LIABILITIES AND OTHER MATTERS
Other Contingent Liabilities
Other Contingent Liabilities (Letters of credit)
The Company had other contingent liabilities totaling approximately $1 million at June 30, 2026, primarily related to outstanding letters of credit.
Other Legal and Tax Matters
Various subsidiaries of the Company are involved in litigation and tax examinations incidental to their business activities. While the outcome of these matters cannot be predicted with certainty, management is vigorously defending the matters and does not currently expect that any of them will have a material adverse effect on the Company’s business, results of operations, or financial position. However, should one or more of these matters be resolved in a manner adverse to management’s current expectation, the effect on the Company’s results of operations for a particular fiscal reporting period could be material.
Advances to Suppliers
In many sourcing regions where the Company operates, it provides agronomy services and seasonal advances of seed, seedlings, fertilizer, and other supplies to tobacco farmers for crop production, or makes seasonal cash advances to farmers for the procurement of those inputs. These advances are short term, are repaid upon delivery of tobacco to the Company, and are reported in advances to suppliers in the consolidated balance sheets. In several regions, the Company has made long-term advances to tobacco farmers to finance curing barns and other farm infrastructure. In some years, due to low crop yields and other factors, individual farmers may not deliver sufficient volumes of tobacco to fully repay their seasonal advances, and the Company may extend repayment of those advances into future crop years. The long-term portion of advances is included in other noncurrent assets in the consolidated balance sheets. Both the current and the long-term portions of advances to suppliers are reported net of allowances recorded when the Company determines that amounts outstanding are not likely to be collected. Short-term and long-term advances to suppliers totaled $120 million at June 30, 2026, $98 million at June 30, 2025, and $196 million at March 31, 2026. The related valuation allowances totaled $16 million at June 30, 2026, $18 million at June 30, 2025, and $16 million at March 31, 2026, and were estimated based on the Company’s historical loss information and crop projections. The allowances were increased by net provisions of $1.8 million and $0.1 million in the three-month periods ended June 30, 2026 and 2025, respectively. These net provisions are included in selling, general, and administrative expenses in the consolidated statements of income. Interest on advances is recognized in earnings as it is earned.
Recoverable Value-Added Tax Credits
In many foreign countries, the Company’s local operating subsidiaries pay significant amounts of valued added tax (“VAT”) on purchases of unprocessed and processed tobacco, crop inputs, packing materials, and various other goods and services. In some countries, VAT is a national tax, and in other countries it is assessed at the state level. Items subject to VAT vary from jurisdiction to jurisdiction, as do the rates at which the tax is assessed. When tobacco is sold to customers in the country of origin, the operating subsidiaries generally collect VAT on those sales. The subsidiaries are normally permitted to offset their VAT payments against the collections and remit only the incremental VAT collections to the tax authorities. When tobacco is sold for export, VAT is normally not assessed. In countries where tobacco sales are predominately for export markets, VAT collections
9


generated on downstream sales are often not sufficient to fully offset the subsidiaries’ VAT payments. In those situations, unused VAT credits can accumulate. Some jurisdictions have procedures that allow companies to apply for refunds of unused VAT credits from the tax authorities, but the refund process often takes an extended period of time and it is not uncommon for refund applications to be challenged or rejected in part on technical grounds. Other jurisdictions may permit companies to sell or transfer unused VAT credits to third parties in private transactions, although approval for such transactions must normally be obtained from the tax authorities, limits on the amounts that can be transferred may be imposed, and the proceeds realized may be heavily discounted from the face value of the credits. Due to these factors, local operating subsidiaries in some countries can accumulate significant balances of VAT credits over time. The Company reviews these balances on a regular basis and records valuation allowances on the credits to reflect amounts that are not expected to be recovered, as well as discounts anticipated on credits that are expected to be sold or transferred. At June 30, 2026, the aggregate balance of recoverable tax credits held by the Company’s subsidiaries totaled approximately $80 million, $78 million at June 30, 2025, and $66 million at March 31, 2026. The related valuation allowances totaled approximately $23 million at June 30, 2026, $21 million at June 30, 2025, and $22 million at March 31, 2026. The net balances are reported in other current assets and other noncurrent assets in the consolidated balance sheets.
Stock Repurchase Program
On November 7, 2024, the Company's Board of Directors approved a stock repurchase program for the purchase of up to $100 million in common stock in open market or privately negotiated transactions at prices not exceeding prevailing market rates through November 15, 2026, subject to market conditions and other factors. The program had $97 million of remaining capacity for repurchases of common stock at June 30, 2026.
Trade Receivable Sales
During the second quarter of fiscal year 2026, the Company entered into an agreement to sell certain trade receivables, at its discretion, to a third-party financial institution at a discount. The transactions have no recourse and qualify as a true sale, meaning upon receipt of the settlement amount, the associated receivable is removed from the balance sheet and the discount is recognized as an expense in selling, general, and administrative expense on the consolidated statements of income. During the three months ended June 30, 2026, the Company sold $52.9 million of receivables and recorded discounts of $0.6 million.

10


NOTE 5.   EARNINGS PER SHARE
    The following table sets forth the computation of basic and diluted earnings (loss) per share:
Three Months Ended June 30,
(in thousands, except share and per share data)20262025
Basic Earnings (Loss) Per Share
Numerator for basic earnings (loss) per share
Net income (loss) attributable to Universal Corporation$(5,016)$8,497 
Denominator for basic earnings (loss) per share
Weighted average shares outstanding25,081,430 24,999,570 
Basic earnings (loss) per share$(0.20)$0.34 
Diluted Earnings (Loss) Per Share
Numerator for diluted earnings (loss) per share
Net income (loss) attributable to Universal Corporation$(5,016)$8,497 
Denominator for diluted earnings (loss) per share:
Weighted average shares outstanding25,081,430 24,999,570 
Effect of dilutive securities
Employee and outside director share-based awards 132,287 
Denominator for diluted earnings (loss) per share25,081,430 25,131,857 
Diluted earnings (loss) per share$(0.20)$0.34 
NOTE 6.   INCOME TAXES
The Company operates in the United States and many foreign countries and is subject to the tax laws of many jurisdictions. Changes in tax laws, including modifications to dividend withholding tax laws, or the interpretation of tax laws can affect the Company’s earnings, as can the resolution of pending and contested tax issues.
In various countries in which the Company operates, legislation has been enacted incorporating the Organisation for Economic Co-operation and Development’s Global Anti-Base Erosion Pillar Two model rules establishing a 15% global minimum tax. The estimated tax impact of such legislation has been included in the provision for income taxes and is not material. This is treated as a period cost and does not have any additional deferred taxes related to these new laws.
Three months ended June 30, 2026
The Company's consolidated effective income tax rate for the three months ended June 30, 2026 was 35.1%.
Three months ended June 30, 2025
    The Company's consolidated effective income tax rate for the three a months ended June 30, 2025 was 27.1%.
The Company’s consolidated effective tax rate is affected by various factors, including the mix and timing of domestic and foreign earnings, discrete items, and the effect of exchange rate changes on taxes.
11


NOTE 7.   GOODWILL AND OTHER INTANGIBLES
The Company's changes in goodwill at June 30, 2026 and 2025 consisted of the following:
(in thousands of dollars)Three Months Ended June 30,
20262025
Balance at beginning of fiscal year$172,695 $213,840 
Foreign currency translation adjustment
(16)24 
Balance at end of period$172,679 $213,864 
The Company's intangible assets primarily consist of capitalized customer-related intangibles, trade names, proprietary developed technology and noncompetition agreements. The Company's intangible assets subject to amortization consisted of the following at June 30, 2026 and 2025 and at March 31, 2026:
(in thousands, except useful life)June 30, 2026
Useful Life (years)Gross Carrying ValueAccumulated AmortizationNet Carrying Value
Customer relationships1113$86,500 $(42,818)$43,682 
Trade names511,100 (11,100) 
Developed technology139,300 (6,444)2,856 
Noncompetition agreements44,000 (4,000) 
Other5709 (654)55 
Total intangible assets$111,609 $(65,016)$46,593 
June 30, 2025
Useful Life (years)Gross Carrying ValueAccumulated AmortizationNet Carrying Value
Customer relationships1113$86,500 $(35,087)$51,413 
Trade names511,100 (10,710)390 
Developed technology139,300 (6,098)3,202 
Noncompetition agreements44,000 (3,813)187 
Other5866 (821)45 
Total intangible assets$111,766 $(56,529)$55,237 
March 31, 2026
Useful Life (years)Gross Carrying ValueAccumulated AmortizationNet Carrying Value
Customer relationships1113$86,500 $(40,885)$45,615 
Trade names511,100 (11,100) 
Developed technology139,300 (6,358)2,942 
Noncompetition agreements44,000 (4,000) 
Other5694 (647)47 
Total intangible assets$111,594 $(62,990)$48,604 
Intangible assets are amortized on a straight-line basis over the asset's estimated useful economic life, as noted above.
The Company's amortization expense for intangible assets for the three months ended June 30, 2026 and 2025 was:
(in thousands of dollars)Three Months Ended June 30,
20262025
Amortization Expense$2,026 $2,663 
12


Amortization expense for the developed technology intangible asset is recorded in cost of goods sold in the consolidated statements of income. The amortization expense for other intangible assets is recorded in selling, general, and administrative expenses in the consolidated statements of income.
As of June 30, 2026, the expected future amortization expense for intangible assets was as follows:
Fiscal Year (in thousands of dollars)
2027 (excluding the three months ended June 30, 2026)
$6,081 
20288,109 
20298,077 
20308,077 
2031 and thereafter16,249 
Total expected future amortization expense$46,593 
NOTE 8.   DERIVATIVES AND HEDGING ACTIVITIES
Universal is exposed to various risks in its worldwide operations and uses derivative financial instruments to manage two specific types of risks – interest rate risk and foreign currency exchange rate risk. Interest rate risk has been managed by entering into interest rate swap agreements, and foreign currency exchange rate risk has been managed by entering into forward and option foreign currency exchange contracts. However, the Company’s policy also permits other types of derivative instruments. In addition, foreign currency exchange rate risk is also managed through strategies that do not involve derivative instruments, such as using local borrowings and other approaches to minimize net monetary positions in non-functional currencies. The disclosures below provide additional information about the Company’s hedging strategies, the derivative instruments used, and the effects of these activities on the consolidated statements of income and comprehensive income and the consolidated balance sheets. In the consolidated statements of cash flows, the cash flows associated with all of these activities are reported in net cash provided (used) by operating activities.
Cash Flow Hedging Strategy for Interest Rate Risk
In December 2025, the Company entered into receive-floating/pay-fixed interest rate swap agreements that were designated and qualify as hedges of the exposure to changes in interest payment cash flows created by fluctuations in variable interest rates on two outstanding non-amortizing bank term loans that were funded as part of a new bank credit facility in December 2025. Although no significant ineffectiveness is expected with this hedging strategy, the effectiveness of the interest rate swaps is evaluated on a quarterly basis. At June 30, 2026, the total notional amount of the interest rate swaps was $310 million, which corresponded to a portion of the aggregate outstanding balance of the term loans.
Previously, the Company entered into receive-floating/pay-fixed interest rate swap agreements in December 2022 that were designated and qualified as cash flow hedges for two non-amortizing bank loans that were repaid concurrent with the entry into the Company's new bank credit facility in December 2025. Those swap agreements, which had an aggregate notional amount of $310 million, corresponding to a portion of the principal balance on the repaid loans, were terminated concurrent with the inception of the new swap agreements. The fair value of the previous swap agreements, approximately $1.0 million, was paid to the counterparties in December 2025 upon termination and is being amortized from accumulated other comprehensive loss into earnings as interest expense through the original maturity dates of those agreements.
Cash Flow Hedging Strategy for Foreign Currency Exchange Rate Risk Related to Sales of Crop Inputs, Forecast Purchases of Tobacco, and Related Processing Costs
The majority of the tobacco production in most countries outside the United States where Universal operates is sold in export markets at prices denominated in U.S. dollars. However, sales of crop inputs (such as seeds and fertilizers) to farmers, purchases of tobacco from farmers, and most processing costs (such as labor and energy) in those countries are usually denominated in the local currency. Changes in exchange rates between the U.S. dollar and the local currencies where tobacco is grown and processed affect the ultimate U.S. dollar sales of crop inputs and cost of processed tobacco. From time to time, the Company enters into forward and option contracts to buy U.S. dollars and sell the local currency at future dates that coincide with the sale of crop inputs to farmers. In the case of forecast purchases of tobacco and the related processing costs, the Company enters into forward and option contracts to sell U.S. dollars and buy the local currency at future dates that coincide with the expected timing of a portion of the tobacco purchases and processing costs. These strategies offset the variability of future U.S. dollar cash flows for sales of crop inputs, tobacco purchases, and processing costs for the foreign currency notional amount hedged. These hedging strategies have been used mainly for tobacco purchases, processing costs, and sales of crop inputs in Brazil. Additionally, the Company from time to time hedges a portion of the forecasted local currency-denominated operating costs in Brazil and Mexico by entering into derivative contracts to buy the local currencies and sell the U.S. dollar.
13


The aggregate U.S. dollar notional amounts of forward and option contracts entered into for these purposes during the three-month periods in fiscal years 2027 and 2026 was as follows:
Three Months Ended June 30,
(in millions of dollars)20262025
Tobacco purchases$82.1 $42.2 
Processing costs14.6 8.3 
Operating costs12.4  
Total
$109.1 $50.5 
Fluctuations in exchange rates and in the amount and timing of fixed-price orders from customers for their purchases from individual crop years routinely cause variations in the U.S. dollar notional amount of forward contracts entered into from one year to the next. Contracts related to tobacco purchases and crop input sales were designated and qualified as hedges of the future cash flows associated with the forecast purchases of tobacco. As a result, changes in fair values of the forward contracts have been recognized in comprehensive income as they occurred, but only recognized in earnings as a component of cost of goods sold upon sale of the related tobacco to third-party customers. The Company de-designates ineffective tobacco purchases and crop input sales hedges to selling, general, and administrative expense when the forecasted tobacco purchases or crop input sales are no longer expected to occur.
The table below presents the expected timing of when the remaining accumulated other comprehensive gains and losses as of June 30, 2026 for cash flows hedges of tobacco purchases and crop input sales are expected to be recognized in earnings.
Hedging ProgramCrop YearGeographic Location(s)Fiscal Year Earnings
Tobacco purchases2027Brazil2028
Tobacco purchases2026Brazil2027
Crop input sales2027Brazil2028
Crop input sales2026Brazil2027
Forward contracts related to processing and operating costs have not been designated as hedges, and gains and losses on those contracts have been recognized in earnings on a mark-to-market basis.
Hedging Strategy for Foreign Currency Exchange Rate Risk Related to Net Local Currency Monetary Assets and Liabilities of Foreign Subsidiaries
Most of the Company’s foreign subsidiaries transact the majority of their sales in U.S. dollars and finance the majority of their operating requirements with U.S. dollar borrowings, and therefore use the U.S. dollar as their functional currency. These subsidiaries normally have certain monetary assets and liabilities on their balance sheets that are denominated in the local currency. Those assets and liabilities can include cash and cash equivalents, accounts receivable and accounts payable, advances to farmers and suppliers, deferred income tax assets and liabilities, recoverable value-added taxes, operating lease liabilities, and other items. Net monetary assets and liabilities denominated in the local currency are remeasured into U.S. dollars each reporting period, generating gains and losses that the Company records in earnings as a component of selling, general, and administrative expenses. The level of net monetary assets or liabilities denominated in the local currency normally fluctuates throughout the year based on the operating cycle, but it is most common for monetary assets to exceed monetary liabilities, sometimes by a significant amount. When this situation exists and the local currency weakens against the U.S. dollar, remeasurement losses are generated. Conversely, remeasurement gains are generated on a net monetary asset position when the local currency strengthens against the U.S. dollar. To manage a portion of its exposure to currency remeasurement gains and losses, the Company enters into forward contracts to buy or sell the local currency at future dates coinciding with expected changes in the overall net local currency monetary asset position of the subsidiary. Gains and losses on the forward contracts are recorded in earnings as a component of selling, general, and administrative expenses for each reporting period as they occur, and thus directly offset the related remeasurement losses or gains in the consolidated statements of income for the notional amount hedged. The Company does not designate these contracts as hedges for accounting purposes. The contracts are generally arranged to hedge the subsidiary's projected exposure to currency remeasurement risk for specified periods of time, and new contracts are entered as necessary throughout the year to replace previous contracts as they mature. The Company is currently using forward currency contracts to manage its exposure to currency remeasurement risk in Brazil. The total notional amounts of contracts outstanding at June 30, 2026 and 2025, and March 31, 2026, were approximately $31.4 million, $29.1 million, and $24.2 million, respectively. To further mitigate currency remeasurement exposure, the Company’s foreign subsidiaries may utilize short-term local currency financing during certain periods. This strategy, while not involving the use of derivative instruments, is intended to minimize the
14


subsidiary’s net monetary position by financing a portion of the local currency monetary assets with local currency monetary liabilities, thus hedging a portion of the overall position.
Several of the Company’s foreign subsidiaries transact the majority of their sales and finance the majority of their operating requirements in their local currency, and therefore use their respective local currencies as the functional currency for reporting purposes. From time to time, these subsidiaries sell tobacco to customers in transactions that are not denominated in the functional currency. In those situations, the subsidiaries routinely enter into forward exchange contracts to offset currency risk for the period of time that a fixed-price order and the related trade account receivable are outstanding with the customer. The contracts are not designated as hedges for accounting purposes.
Effect of Derivative Financial Instruments on the Consolidated Statements of Income
The table below outlines the effects of the Company’s use of derivative financial instruments on the consolidated statements of income:
Three Months Ended June 30,
(in thousands of dollars)20262025
Cash Flow Hedges - Interest Rate Swap Agreements
Derivative
Effective Portion of Hedge
Gain (loss) recorded in accumulated other comprehensive loss$4,131 $(1,693)
Gain (loss) reclassified from accumulated other comprehensive loss into earnings
$70 $692 
Gain on terminated interest rate swaps amortized from accumulated other comprehensive loss into earnings
$(98)$688 
Location of gain (loss) reclassified from accumulated other comprehensive loss into earnings
Interest expense
Ineffective Portion of Hedge
Gain (loss) recognized in earnings$ $ 
Location of gain (loss) recognized in earningsSelling, general and administrative expenses
Hedged Item
Description of hedged itemFloating rate interest payments on term loans
Cash Flow Hedges - Foreign Currency Exchange Contracts
Derivative
Effective Portion of Hedge
Gain (loss) recorded in accumulated other comprehensive loss$(2,930)$952 
Gain (loss) reclassified from accumulated other comprehensive loss into earnings
$(96)$(212)
Location of gain (loss) reclassified from accumulated other comprehensive loss into earnings
Cost of goods sold
Ineffective Portion and Early De-designation of Hedges
Gain (loss) recognized in earnings$ $ 
Location of gain (loss) recognized in earningsSelling, general and administrative expenses
Hedged Item
Description of hedged item
 Forecast purchases of tobacco and sales of crop inputs in Brazil
Derivatives Not Designated as Hedges - Foreign Currency Exchange Contracts
Gain (loss) recognized in earnings$(281)$830 
Location of gain (loss) recognized in earningsSelling, general and administrative expenses
15


For the interest rate swap agreements, the effective portion of the gain or loss on the derivative is recorded in accumulated other comprehensive loss and any ineffective portion is recorded in selling, general and administrative expenses.
For the forward foreign currency exchange contracts designated as cash flow hedges of tobacco purchases and the crop input sales in Brazil, a net hedge loss of approximately $4.1 million remained in accumulated other comprehensive loss at June 30, 2026. That balance reflects gains and losses on contracts related to the 2027 and 2026 Brazil crop, and the 2027 and 2026 Brazil crop input sales, less the amounts reclassified to earnings related to tobacco sold through June 30, 2026. Based on the hedging strategy, as the gain or loss is recognized in earnings, it is expected to be offset by a change in the direct cost for the tobacco or by a change in sales prices if the strategy has been mandated by the customer. Generally, margins on the sale of the tobacco will not be significantly affected.
Effect of Derivative Financial Instruments on the Consolidated Balance Sheets
The table below outlines the effects of the Company’s derivative financial instruments on the consolidated balance sheets at June 30, 2026 and 2025, and March 31, 2026:
Derivatives in a Fair Value Asset PositionDerivatives in a Fair Value Liability Position
Balance
Sheet
Location
Fair Value as ofBalance
Sheet
Location
Fair Value as of
(in thousands of dollars)June 30, 2026June 30, 2025March 31, 2026June 30, 2026June 30, 2025March 31, 2026
Derivatives Designated as Hedging Instruments
Interest rate swap agreements Other
non-current
assets
$5,014 $ $953 Other
long-term
liabilities
$ $602 $ 
Foreign currency exchange contractsOther
current
assets
 1,840 307 Accounts
payable and
accrued
expenses
3,026 1,297 321 
Total$5,014 $1,840 $1,260 $3,026 $1,899 $321 
Derivatives Not Designated as Hedging Instruments
Foreign currency exchange contractsOther
current
assets
$144 $947 $458 Accounts
payable and
accrued
expenses
$1,196 $634 $273 
Total$144 $947 $458 $1,196 $634 $273 
Substantially all of the Company's foreign exchange derivative instruments are subject to master netting arrangements whereby the right to offset occurs in the event of default by a participating party. The Company has elected to present these contracts on a gross basis in the consolidated balance sheets.
NOTE 9.   FAIR VALUE MEASUREMENTS
Universal measures certain financial and nonfinancial assets and liabilities at fair value based on applicable accounting guidance. The financial assets and liabilities measured at fair value include money market funds, trading securities associated with deferred compensation plans, interest rate swap agreements, and forward foreign currency exchange contracts. The application of the fair value guidance to nonfinancial assets and liabilities primarily includes the determination of fair values for goodwill and long-lived assets when indicators of potential impairment are present.
    Under the accounting guidance, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The framework for measuring fair value is based on a fair value hierarchy that distinguishes between observable inputs and unobservable inputs. Observable inputs are based on market data obtained from independent sources. Unobservable inputs require the Company to make its own assumptions about the value placed on an asset or liability by market participants because little or no market data exists.
16


There are three levels within the fair value hierarchy:
LevelDescription
1quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date;
2quoted prices in active markets for similar assets or liabilities, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability; and
3unobservable inputs for the asset or liability.
    As permitted under the accounting guidance, the Company uses net asset value per share ("NAV") as a practical expedient to measure the fair value of its money market funds. The fair values for those funds are presented under the heading "NAV" in the tables that follow in this disclosure. In measuring the fair value of liabilities, the Company considers the risk of non-performance in determining fair value. Universal has not elected to report at fair value any financial instruments or any other assets or liabilities that are not required to be reported at fair value under current accounting guidance.
Recurring Fair Value Measurements
At June 30, 2026 and 2025, and at March 31, 2026, the Company had certain financial assets and financial liabilities that were required to be measured and reported at fair value on a recurring basis. These assets and liabilities are listed in the tables below and are classified based on how their values were determined under the fair value hierarchy or the NAV practical expedient:
June 30, 2026
Fair Value Hierarchy
(in thousands of dollars)NAVLevel 1Level 2Level 3Total
Assets
Money market funds
$13 $ $ $ $13 
Trading securities associated with deferred compensation plans
 13,007   13,007 
Interest rate swap agreements
  5,014  5,014 
Foreign currency exchange contracts
  144  144 
Total financial assets measured and reported at fair value
$13 $13,007 $5,158 $ $18,178 
Liabilities
Foreign currency exchange contracts
$ $ $4,222 $ $4,222 
Total financial liabilities measured and reported at fair value
$ $ $4,222 $ $4,222 
June 30, 2025
Fair Value Hierarchy
(in thousands of dollars)NAVLevel 1Level 2Level 3Total
Assets
Money market funds
$149 $ $ $ $149 
Trading securities associated with deferred compensation plans
 12,078   12,078 
Foreign currency exchange contracts
  2,787  2,787 
Total financial assets measured and reported at fair value
$149 $12,078 $2,787 $ $15,014 
Liabilities
Interest rate swap agreements
$ $ $602 $ $602 
Foreign currency exchange contracts
  1,931  1,931 
Total financial liabilities measured and reported at fair value
$ $ $2,533 $ $2,533 

17


March 31, 2026
Fair Value Hierarchy
(in thousands of dollars)NAVLevel 1Level 2Level 3Total
Assets
Money market funds
$10 $ $ $ $10 
Trading securities associated with deferred compensation plans
 11,630   11,630 
Interest rate swap agreements
  953  953 
Foreign currency exchange contracts
  765  765 
Total financial assets measured and reported at fair value
$10 $11,630 $1,718 $ $13,358 
Liabilities
Foreign currency exchange contracts
$ $ $594 $ $594 
Total financial liabilities measured and reported at fair value
$ $ $594 $ $594 
Money market funds
The fair value of money market funds, which are reported in cash and cash equivalents in the consolidated balance sheets, is based on NAV, which is the amount at which the funds are redeemable and is used as a practical expedient for fair value. These funds are not classified in the fair value hierarchy, but are disclosed as part of the fair value table above.
Trading securities associated with deferred compensation plans
Trading securities represent mutual fund investments that are matched to employee deferred compensation obligations. These investments are bought and sold as employees defer compensation, receive distributions, or make changes in the funds underlying their accounts. Quoted market prices (Level 1) are used to determine the fair values of the mutual funds.
Interest rate swap agreements
The fair values of interest rate swap agreements are determined based on dealer quotes using a discounted cash flow model matched to the contractual terms of each instrument. Since inputs to the model are observable and significant judgment is not required in determining the fair values, interest rate swaps are classified within Level 2 of the fair value hierarchy.
Foreign currency exchange contracts
The fair values of forward and option foreign currency exchange contracts are also determined based on dealer quotes using a discounted cash flow model matched to the contractual terms of each instrument. Since inputs to the model are observable and significant judgment is not required in determining the fair values, forward and option foreign currency exchange contracts are classified within Level 2 of the fair value hierarchy.
Long-term Debt
The following table summarizes the fair and carrying value of the Company’s long-term debt, and if applicable any current portion, at each of the balance sheet dates June 30, 2026, and 2025 and March 31, 2026:
(in millions of dollars)June 30, 2026June 30, 2025March 31, 2026
Fair market value of long term obligations$613 $618 $615 
Carrying value of long term obligations$620 $620 $620 
The Company estimates the fair value of its long-term debt using Level 2 inputs which are based upon quoted market prices for the same or similar obligations or on calculations that are based on the current interest rates available to the Company for debt of similar terms and maturities.
Nonrecurring Fair Value Measurements
    Assets and liabilities that are measured at fair value on a nonrecurring basis primarily relate to long-lived assets, right-of-use operating lease assets and liabilities, goodwill and intangibles, and other current and noncurrent assets. These assets and liabilities fair values are also evaluated for impairment when potential indicators of impairment exist. Accordingly, the nonrecurring measurement of the fair value of these assets and liabilities are classified within Level 3 of the fair value hierarchy.
18


Long-Lived Assets
The Company reviews long-lived assets for impairment whenever events, changes in business conditions, or other circumstances provide an indication that such assets may be impaired.

NOTE 10.   PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS
The Company sponsors several defined benefit pension plans covering eligible U.S. salaried employees and certain foreign and other employee groups. These plans provide retirement benefits based primarily on employee compensation and years of service. The Company also sponsors defined benefit plans that provide postretirement health and life insurance benefits for eligible U.S. employees attaining specific age and service levels, although postretirement life insurance is no longer provided for active employees.
The components of the Company’s net periodic benefit cost were as follows:
Pension BenefitsOther Postretirement Benefits
Three Months Ended June 30,Three Months Ended June 30,
(in thousands of dollars)2026202520262025
Service cost$1,403 $1,252 $16 $17 
Interest cost2,350 2,267 266 262 
Expected return on plan assets(2,871)(3,027)(7)(11)
Net amortization and deferral323 83 (152)(160)
Net periodic benefit cost
$1,205 $575 $123 $108 
During the three months ended June 30, 2026, the Company made contributions of approximately $0.6 million to its pension plans. Additional contributions of $2.8 million are expected during the remaining nine months of fiscal year 2027.
NOTE 11.   STOCK-BASED COMPENSATION
Under the Company’s 2023 Stock Incentive Plan (“Plan”) directors, officers, and employees of the Company may receive grants and awards of common stock, restricted stock, restricted stock units (“RSUs”), performance share units (“PSUs”), stock appreciation rights, incentive stock options, and non-qualified stock options. With the exception of new hires and promotions, the Company’s practice is to award grants of stock-based compensation to officers on an annual basis at the first regularly-scheduled meeting of the Compensation and Human Resources Committee of the Board of Directors (the “Compensation Committee”) in the fiscal year following the public release of the Company’s financial results for the prior fiscal year. In recent years, the Compensation Committee has awarded only grants of RSUs and PSUs. Awards of restricted stock, RSUs, and PSUs are currently outstanding.
RSUs awarded to officers and employees generally vest 3 years after the grant date. After vesting RSUs are paid out in shares of common stock. Under the terms of the RSU awards, grantees receive dividend equivalents in the form of additional RSUs that vest and are paid out on the same date as the original RSU grant. The PSUs vest at the end of a performance period of 3 years that begins with the year of the grant, are paid out in shares of common stock shortly after the vesting date, and do not carry rights to dividends or dividend equivalents prior to vesting. Shares ultimately paid out under PSU grants are dependent on the achievement of predetermined performance measures established by the Compensation Committee and can range from zero to 150% of the stated award. The Company’s outside directors receive RSUs following the annual meeting of shareholders. RSUs awarded to outside directors vest 1 year after the grant date. Restricted shares vest upon the individual’s retirement from service as a director.
19


During the three-month periods ended June 30, 2026 and 2025, the Company issued the following stock-based awards, representing the regular annual grants to officers and outside directors of the Company:
Three Months Ended June 30,
20262025
RSUs:
Number granted93,352 83,795 
Grant date fair value$53.78 $65.39 
PSUs:
Number granted58,285 50,295 
Grant date fair value$44.93 $56.05 
Fair value expense for stock-based compensation is recognized ratably over the period from grant date to the earlier of (1) the vesting date of the award or (2) the date the grantee is eligible to retire without forfeiting the award. For employees who are already eligible to retire at the date an award is granted, the total fair value of the award is recognized as expense at the date of grant. The Company accounts for forfeitures of stock-based awards as they occur. For the three-month periods ended June 30, 2026 and 2025, the Company recorded total stock-based compensation expense of approximately $5.4 million and $7.6 million, respectively. The Company expects to recognize stock-based compensation expense of approximately $2.6 million during the remaining nine months of fiscal year 2027.
NOTE 12. OPERATING SEGMENTS
Management regularly evaluates the Company’s global business activities, including product and service offerings to its customers, as well as senior management’s operational and financial responsibilities. Assessments include an analysis of how its Chief Operating Decision Maker (“CODM”) measures business performance and allocates resources. As a result of this analysis, senior management has determined the Company conducts operations across two reportable operating segments, Tobacco Operations and Ingredients Operations.
The Tobacco Operations segment activities involve contracting, procuring, processing, packing, storing, and shipping leaf tobacco for sale to, or for the account of, manufacturers of consumer tobacco products throughout the world. Through various operating subsidiaries located in tobacco-growing countries around the world and significant ownership interests in unconsolidated affiliates, the Company processes and/or sells flue-cured and burley tobaccos, dark air-cured tobaccos, and oriental tobaccos. Flue-cured, burley, and oriental tobaccos are used principally in the manufacture of cigarettes, and dark air-cured tobaccos are used mainly in the manufacture of cigars, pipe tobacco, and smokeless tobacco products. Some of these tobacco types are also used in the manufacture of next generation tobacco products that are intended to provide consumers with an alternative to traditional combustible products. The Tobacco Operations segment also provides physical and chemical product testing for tobacco customers. A substantial portion of the Company’s Tobacco Operations’ revenues are derived from sales to a limited number of large, multinational cigarette and cigar manufacturers.
The Ingredients Operations segment provides its customers with a broad variety of plant-based ingredients for both human and pet consumption. The Ingredients Operations segment utilizes a variety of value-added manufacturing processes converting raw materials into a wide spectrum of fruit and vegetable juices, concentrates, dehydrated products, botanical extracts, and flavorings. Customers for the Ingredients Operations segment include large multinational food and beverage companies, smaller independent manufacturers, and retail organizations. FruitSmart, Inc. (“FruitSmart”), Silva International, Inc. (“Silva”), and Shank’s Extracts, LLC d/b/a Universal Ingredients–Shank’s (“Universal Ingredients–Shank’s”) are the primary operations for the Ingredients Operations segment. FruitSmart supplies a broad set of juices, concentrates, pomaces, purees, fruit fibers, seeds, seed powders, and other value-added products to food, beverage, and flavor companies throughout the United States and internationally. Silva procures dehydrated vegetables, fruits, and herbs from around the world and specializes in processing natural materials into custom designed dehydrated vegetable and fruit-based ingredients for a variety of end products. Universal Ingredients–Shank’s offers a diversified portfolio of botanical extracts, distillates, natural flavors, and color for industrial and private label customers worldwide, and is known for their significant vanilla expertise. Universal Ingredients–Shank’s is also equipped to offer customers custom bottling and packaging for their products.
Universal incurs corporate overhead expenses related to senior management, sales, finance, legal, and other functions that are centralized at its corporate headquarters, as well as functions performed at several sales and administrative offices around the world. These overhead expenses are currently allocated to the reportable operating segments, generally on the basis of projected annual financial and operational performance, including volumes planned to be purchased and/or processed.
20


Management believes this method of allocation is currently representative of the value of the related services provided to the operating segments. The CODM, which has been identified as a group comprised of the Company’s Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer, currently evaluates the performance of the operating segments based on operating income after allocated overhead expenses, plus equity in the pretax earnings of unconsolidated affiliates (“Segment Operating Income”). The CODM also uses Segment Operating Income for planning, forecasting, and allocating capital and other resources to the operating segments.
Reportable segment data as of, or for, each period presented in the consolidated statements of income and comprehensive income, the consolidated balance sheets, and the consolidated statements of cash flows is as follows:
Three Months Ended June 30, 2026Three Months Ended June 30, 2025
Tobacco OperationsIngredients OperationsConsolidatedTobacco OperationsIngredients OperationsConsolidated
Sales and other operating revenues$437,128 $86,651 $523,779 $504,696 $89,066 $593,762 
Cost of goods sold(367,087)(73,604)(440,691)(407,867)(71,768)(479,635)
Selling, general and administrative expenses(46,064)(10,521)(56,585)(44,754)(12,037)(56,791)
Corporate overhead allocated to the segments(21,021)(3,186)(24,207)(18,840)(3,561)(22,401)
Equity in pretax earnings (loss) of unconsolidated affiliates(1)
510  510 2,435  2,435 
Segment operating income (loss)3,466 (660)2,806 35,670 1,700 37,370 
Deduct: Equity in pretax (earnings) loss of unconsolidated affiliates(1)
(510)(2,435)
Restructuring and impairment costs (2)
 (1,122)
Consolidated operating income$2,296 $33,813 
(1)Equity in pretax earnings (loss) of unconsolidated affiliates is included in segment operating income (Tobacco Operations), but is reported below consolidated operating income and excluded from that total in the consolidated statements of income and comprehensive income.
(2)Restructuring and impairment costs are excluded from segment operating income, but are included in consolidated operating income in the consolidated statements of income and comprehensive income. See Note 2 for additional information.
Segment AssetsAccounts Receivable, net
June 30,
2026
June 30,
2025
March 31,
2026
June 30,
2026
June 30,
2025
March 31,
2026
Tobacco Operations$2,563,429 $2,652,407 $2,300,491 $296,659 $366,317 $508,247 
Ingredients Operations472,038 536,900 466,276 51,377 57,840 55,617 
Consolidated total$3,035,467 $3,189,307 $2,766,767 $348,036 $424,157 $563,864 
Goodwill, netIntangibles, net
June 30,
2026
June 30,
2025
March 31,
2026
June 30,
2026
June 30,
2025
March 31,
2026
Tobacco Operations$97,672 $97,796 $97,688 $55 $45 $47 
Ingredients Operations75,007 116,068 75,007 46,538 55,192 48,557 
Consolidated total$172,679 $213,864 $172,695 $46,593 $55,237 $48,604 
Capital ExpendituresDepreciation and Amortization
Three Months Ended June 30,Three Months Ended June 30,
2026202520262025
Tobacco Operations$12,535 $7,402 $7,667 $8,216 
Ingredients Operations3,391 4,651 5,093 5,366 
Consolidated total$15,926 $12,053 $12,760 $13,582 
21


NOTE 13. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
    The following table summarizes the changes in the accumulated balances for each component of accumulated other comprehensive income (loss) attributable to the Company for the three months ended June 30, 2026 and 2025:
Three Months Ended June 30,
(in thousands of dollars)20262025
Foreign currency translation:
Balance at beginning of year$(37,114)$(42,639)
Other comprehensive income (loss) attributable to Universal Corporation:
Net gain (loss) on foreign currency translation(1,366)8,503 
Less: Net (gain) loss on foreign currency translation attributable to noncontrolling interests90 (23)
Other comprehensive income (loss) attributable to Universal Corporation, net of income taxes(1,276)8,480 
Balance at end of period$(38,390)$(34,159)
Foreign currency hedge:
Balance at beginning of year$(1,078)$(4,914)
Other comprehensive income (loss) attributable to Universal Corporation:
Net gain (loss) on derivative instruments (net of tax (expense) benefit of $683 and $(659))
(3,008)3,381 
Reclassification of (gain) loss to earnings (net of tax expense (benefit) of $(29) and $54) (1)
123 (524)
Other comprehensive income (loss) attributable to Universal Corporation, net of income taxes(2,885)2,857 
Balance at end of period$(3,963)$(2,057)
Interest rate hedge:
Balance at beginning of year$44 $2,834 
Other comprehensive income (loss) attributable to Universal Corporation:
Net gain (loss) on derivative instruments (net of tax (expense) benefit of $(1,088) and $446)
3,044 (1,247)
Reclassification of (gain) loss to earnings (net of tax expense (benefit) of $(7) and $363) (2)
20 (1,017)
Other comprehensive income (loss) attributable to Universal Corporation, net of income taxes3,064 (2,264)
Balance at end of period$3,108 $570 
Pension and other postretirement benefit plans:
Balance at beginning of year$(34,964)$(35,332)
Other comprehensive income (loss) attributable to Universal Corporation:
Amortization included in earnings (net of tax expense (benefit) of $(44) and $38)(3)
113 (361)
Other comprehensive income (loss) attributable to Universal Corporation, net of income taxes113 (361)
Balance at end of period$(34,851)$(35,693)
Total accumulated other comprehensive loss at end of period$(74,096)$(71,339)
(1)    Gain (loss) on foreign currency cash flow hedges related to forecast purchases of tobacco and crop input sales is reclassified from accumulated other comprehensive income (loss) to cost of goods sold when the tobacco is sold to customers. See Note 8 for additional information.
(2)    Gain (loss) on interest rate cash flow hedges is reclassified from accumulated other comprehensive income (loss) to interest expense when the related interest payments are made on the underlying debt, or as amortized to interest expense over the period to original maturity for terminated swap agreements. See Note 8 for additional information.
(3)    This accumulated other comprehensive income (loss) component is included in the computation of net periodic benefit cost. See Note 10 for additional information.
22


NOTE 14. CHANGES IN SHAREHOLDERS' EQUITY AND NONCONTROLLING INTERESTS IN SUBSIDIARIES
A reconciliation of the changes in Universal Corporation shareholders’ equity and noncontrolling interests in subsidiaries for the three months ended June 30, 2026 and 2025 is as follows:
Three Months Ended June 30, 2026Three Months Ended June 30, 2025
(in thousands of dollars)Universal CorporationNon-controlling InterestsTotalUniversal CorporationNon-controlling InterestsTotal
Balance at beginning of three-month period$1,415,400 $45,724 $1,461,124 $1,458,556 $41,982 $1,500,538 
Changes in common stock
Repurchase of common stock(723) (723)   
Accrual of stock-based compensation5,378  5,378 7,575  7,575 
Withholding of shares from stock-based compensation for grantee income taxes
(2,504) (2,504)(4,017) (4,017)
Dividend equivalents on RSUs225  225 314  314 
Changes in retained earnings
Net income (loss)(5,016)(3,334)(8,350)8,497 5,870 14,367 
Cash dividends declared
 Common stock(20,699) (20,699)(20,406) (20,406)
Repurchase of common stock(2,023) (2,023)   
Dividend equivalents on RSUs(225) (225)(314) (314)
Other comprehensive income (loss)(984)(90)(1,074)8,712 23 8,735 
Other changes in noncontrolling interests
Dividends paid to noncontrolling shareholders
 (8,235)(8,235) (7,203)(7,203)
Balance at end of period$1,388,829 $34,065 $1,422,894 $1,458,917 $40,672 $1,499,589 
23


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Unless the context otherwise requires, the terms “we,” “our,” “us,” or “Universal” or the “Company” refer to Universal Corporation together with its subsidiaries. This Quarterly Report on Form 10-Q ("Form 10-Q") and the following “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Among other things, these statements relate to the Company’s financial condition, results of operation, and future business plans, operations, opportunities, and prospects. In addition, the Company and its representatives may from time to time make written or oral forward-looking statements, including statements contained in other filings with the Securities and Exchange Commission (the "SEC") and in reports to shareholders. These forward-looking statements are generally identified by the use of words such as we “expect,” “believe,” “anticipate,” “could,” “should,” “may,” “plan,” “will,” “predict,” “estimate,” and similar expressions or words of similar import. These forward-looking statements are based upon management’s current knowledge and assumptions about future events and involve risks and uncertainties that could cause actual results, performance, or achievements to be materially different from any anticipated results, prospects, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: product purchased not meeting quality and quantity requirements; reliance on a few large customers; anticipated levels of demand for and supply of our products and services; tobacco growing conditions and customer requirements; major shifts in customer requirements for leaf tobacco; higher inflation rates, tariffs and other pressures on costs; weather and other conditions; exposure to certain legal, regulatory and financial risks related to climate change; industry-specific risks related to our plant-based ingredients businesses; disruption of our supply chain for our plant-based ingredients; success in pursuing strategic investments or acquisitions and integration of new businesses and the impact of these new businesses on future results; our ability to maintain effective information technology systems and safeguard confidential information; our inability to attract, develop, retain, motivate, and maintain good relationships with our workforce; our dependence on a seasonal workforce; epidemics, pandemics or similar widespread public health concerns; government efforts to regulate the production and consumption of tobacco products; government actions on the sourcing of leaf tobacco; economic and political conditions in the countries in which we and our customers operate, including the ongoing impacts from international conflicts; sustainability considerations from governments and other stakeholders; changes in tax laws in the countries where we do business; failure of our customers or suppliers to repay extensions of credit; changes in exchange rates; changes in interest rates; and low investment performance by our defined benefit pension plan assets and changes in pension plan valuation assumptions. For a further description of factors that may cause actual results to differ materially from such forward-looking statements, see Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 (the "2026 Form 10-K"). We caution investors not to place undue reliance on any forward-looking statements as these statements speak only as of the date when made, and we undertake no obligation to update any forward-looking statements made in this report, except as required by law. This Form 10-Q should be read in conjunction with our 2026 Form 10-K.

Amounts described as net income (loss) and earnings (loss) per diluted share in the following discussion are attributable to Universal Corporation and exclude earnings related to non-controlling interests in subsidiaries. References to adjusted operating income (loss), adjusted net income (loss) attributable to Universal Corporation, adjusted diluted earnings (loss) per share, and the total for segment operating income (loss) are references to non-GAAP financial measures. These measures are not financial measures calculated in accordance with generally accepted accounting principles ("GAAP") and should not be considered as substitutes for operating income (loss), net income (loss) attributable to Universal Corporation, diluted earnings (loss) per share, cash from operating activities or any other operating or financial performance measure calculated in accordance with GAAP, and may not be comparable to similarly-titled measures reported by other companies. Reconciliations of adjusted operating income (loss) to consolidated operating (income), adjusted net income (loss) attributable to Universal Corporation to consolidated net income (loss) attributable to Universal Corporation and adjusted diluted earnings (loss) per share to diluted earnings (loss) per share are provided in Other Items below. In addition, we have provided a reconciliation of the total for segment operating income (loss) to consolidated operating income (loss) in Note 12. "Operating Segments" to the consolidated financial statements. Management evaluates the consolidated Company and segment performance excluding certain significant charges or credits. We believe these non-GAAP financial measures, which exclude items that we believe are not indicative of our core operating results, can provide investors with important information that is useful in understanding our business results and trends. References to net debt, net capitalization, and net debt to net capitalization ratio are also references to non-GAAP financial measures. These measures are not financial measures calculated in accordance with GAAP and should not be considered substitutes for total debt, total capitalization, total debt to total capitalization ratio, or any other operating or financial performance measures calculated in accordance with GAAP, and may not be comparable to similarly-titled measures reported by other companies. Reconciliations of net debt to total debt and net capitalization to total capitalization are provided in Other Items below. We believe these non-GAAP measures are meaningful indicators of liquidity and financial position.

24


Results of Operations
Overview
We are starting fiscal year 2027 with confidence in the long-term strategic direction of our company. We are focused on creating sustainable value through disciplined execution across our businesses. In tobacco, we believe that our long-standing market expertise and measured approach position us well to navigate current oversupply conditions, make prudent buying decisions, and be a trusted, full-service partner to our customers. In ingredients, we are leveraging our platform growth investments and focusing on improving commercial execution, facility utilization, and financial and operational efficiencies. We expect certain of our improvement efforts to continue through fiscal year 2028.

Our results for the quarter ended June 30, 2026, reflected the expected timing and market dynamics in our tobacco business, in comparison to our first quarter fiscal year 2026 results, which we believe were exceptional. Purchasing activity was slower as we and our customers evaluated green tobacco price trends amid oversupply conditions in flue-cured and burley markets and monitored potential weather impacts on next season’s crops. We are pleased with our current customer indications and commitments, and we expect customer demand to remain consistent with our fiscal year 2027 sales plan. In our ingredients business, in the quarter ended June 30, 2026, revenue was down slightly, in comparison to the quarter ended June 30, 2025, and results continued to be negatively affected by persistent consumer market headwinds, high fixed costs at our expanded Lancaster facility, and longer-than-anticipated product development cycles. We continued to implement our initiatives to strengthen the ingredients platform for long-term success, which include enhancements to leadership, systems, operational capabilities, and commercial execution. During the fiscal quarter ended June 30, 2026, our liquidity position remained strong, and our debt levels were down, compared to the quarter ended June 30, 2025, due to reduced working capital usage, driven by tobacco crop purchase timing and lower green tobacco prices.

FINANCIAL HIGHLIGHTS
Three Months Ended June 30,Change
(in millions of dollars, except per share data)20262025%
Consolidated Results
Sales and other operating revenue$523.8 $593.8 (12)%
Cost of goods sold$440.7 $479.6 (8)%
Gross profit margin percentage15.9 %19.2 %-330 bps
Selling, general and administrative expenses$80.8 $79.2 %
Restructuring and impairment costs$— $1.1 (100)%
Operating income$2.3 $33.8 (93)%
Adjusted operating income (non-GAAP)*$2.3 $34.9 (93)%
Net income (loss) attributable to Universal Corporation$(5.0)$8.5 (159)%
Adjusted net income (loss) attributable to Universal Corporation (non-GAAP)*$(5.0)$9.6 (152)%
Diluted earnings (loss) per share$(0.20)$0.34 (159)%
Adjusted diluted earnings (loss) per share (non-GAAP)*$(0.20)$0.38 (153)%
Segment Results
Tobacco operations sales and other operating revenues$437.1 $504.7 (13)%
Tobacco operations operating income$3.5 $35.7 (90)%
Ingredients operations sales and other operating revenues$86.7 $89.1 (3)%
Ingredients operations operating income (loss)$(0.7)$1.7 (139)%
*See Reconciliation of Certain Non-GAAP Financial Measures in Other Items below.
25



Quarter Ended June 30, 2026, compared to Quarter Ended June 30, 2025

Consolidated Results

Revenue decreased by 12%, or $70.0 million, in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025, primarily driven by lower tobacco sales volumes, down 9%, and tobacco sales prices, down 6%.

Operating income decreased by 93%, or $31.5 million, in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025, on a less favorable product mix and lower sales volumes in the Tobacco Operations segment and continued market headwinds and high fixed costs in the Ingredients Operations segment.

Selling, general, and administrative expenses were up by 2%, or $1.6 million, primarily due to unfavorable foreign currency comparisons of $4.8 million and lower recoveries on advances to suppliers of $1.7 million, partially offset by lower compensation costs of $3.0 million and lower legal and professional fees of $1.2 million in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025.

Adjusted operating income was down by $32.6 million and adjusted net income attributable to Universal Corporation was down by $14.6 million in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025, largely on on a less favorable product mix and lower sales volumes in the Tobacco Operations segment and continued market headwinds and high fixed costs in the Ingredients Operations segment.

Tobacco Operations Segment

Our first fiscal quarter is historically a slow quarter for our tobacco business. Revenue decreased by 13%, or $67.6 million, for the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025, primarily on a 9% decrease in tobacco sales volumes due to lower sales of carryover crop tobacco and a 6% decrease in tobacco sales prices due to product mix and lower green tobacco prices. Operating income for the Tobacco Operations segment decreased by 90%, or $32.2 million, for the first quarter of fiscal year 2027, compared to the first quarter of fiscal year 2026, on a less favorable product mix in Asia and lower sales of carryover crop tobacco. Selling, general, and administrative expenses were higher by $1.3 million for the segment mainly due to unfavorable foreign currency comparisons of $4.4 million and lower recoveries on advances to suppliers of $1.7 million, partially offset by lower legal and professional fees of $2.3 million in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025. Corporate overhead costs allocated to the segment were $2.2 million higher in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025, due to a higher percentage allocation of the actual corporate overhead costs to the segment. The allocation of corporate overhead costs is based on projected annual financial and operational performance.

Ingredients Operations Segment

Revenue for the Ingredients Operations segment decreased by 3%, or $2.4 million, for the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025, as sales of certain products were negatively impacted by market headwinds. Operating income for the segment decreased by 139%, or $2.4 million, on product mix and high fixed costs as well as inventory write-downs of $1.4 million. Market headwinds included persistent weakness in the consumer-packaged-goods industry, supply restraints, particularly tight apple markets in the Pacific Northwest, inflationary pressures, and tariff volatility. Selling, general, and administrative expenses were lower by $1.5 million for the segment mainly due to lower compensation costs of $0.8 million and lower intangibles amortization expense of $0.6 million in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025. Corporate overhead costs allocated to the segment were $0.4 million lower in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025, due to a lower percentage allocation of the actual corporate overhead costs to the segment. The allocation of corporate overhead costs is based on projected annual financial and operational performance.

Additional Items

Cost of goods sold decreased by 8%, or $38.9 million, in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025, largely on lower tobacco sales volumes and green tobacco prices.

Interest expense was down by 7%, or $1.3 million, in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025, on lower debt balances.

Restructuring and impairment costs of $1.1 million in the quarter ended June 30, 2025.
26



The consolidated effective tax rate for the three months ended June 30, 2026, was 35%. The consolidated tax rate for the three months ended June 30, 2025, was 27%. The consolidated effective tax rate for the three months ended June 30, 2026, was higher than the consolidated tax rate for the three months ended June 30, 2025, due to various factors, including the mix and timing of domestic and foreign earnings, discrete items including increased withholding taxes on undistributed earnings in Brazil, and the tax deductibility of certain items.

Sustainability

Universal continues to strengthen the foundation of its business through investments in environmental, health, and safety capabilities that support long-term sustainability and operational resilience. Recent initiatives include the implementation of an enhanced global safety management software platform and a comprehensive Global EHS Management System. The new systems improve visibility across operations, support greater consistency and accountability, and strengthen the Company's approach to risk management across its global footprint. By reinforcing a culture of safety, transparency, and continuous improvement, these investments help position Universal for long-term success.

Other Items

Reconciliation of Certain Non-GAAP Financial Measures:
The following tables set forth certain non-recurring items included in reported results to reconcile adjusted operating income to consolidated operating income and adjusted net income (loss) attributable to Universal Corporation to net income (loss) attributable to Universal Corporation:
Adjusted Operating Income Reconciliation
Three Months Ended June 30,
(in thousands)20262025
As Reported: Consolidated operating income$2,296 $33,813 
Restructuring and impairment costs(1)
— 1,122 
As Adjusted operating income (non-GAAP)$2,296 $34,935 
Adjusted Net Income (Loss) Attributable to Universal Corporation and Adjusted Diluted Earnings (Loss) Per Share Reconciliation
(in thousands except for per share amounts)
Three Months Ended June 30,
20262025
As Reported: Net income (loss) attributable to Universal Corporation$(5,016)$8,497 
Restructuring and impairment costs(1)
— 1,122 
Total of non-GAAP adjustments to income (loss) before income taxes— 1,122 
Non-GAAP adjustments to income taxes
Income tax benefit from restructuring and impairment costs(1)(2)
— (35)
Total of income tax impacts for non-GAAP adjustments to income (loss) before income taxes— (35)
As adjusted: Net income (loss) attributable to Universal Corporation (non-GAAP)$(5,016)$9,584 
As reported: Diluted earnings (loss) per share$(0.20)$0.34 
As adjusted: Diluted earnings (loss) per share (non-GAAP)$(0.20)$0.38 
(1)     Restructuring and impairment costs are included in Consolidated operating income in the consolidated statements of income, but excluded for purposes of Adjusted operating income, Adjusted net income (loss) available to Universal Corporation, and Adjusted diluted earnings (loss) per share.
(2)    The income tax effect of non-GAAP adjustments was determined based on the timing and nature of the specific non-GAAP adjustments and their relevant jurisdictional income tax rates (foreign, state, and local) and the applicable U.S. federal income tax rates. The Company considers current and deferred income tax rates to calculate the impact to income taxes for the non-GAAP adjustments.
27


The following table reconciles total debt to net debt and net capitalization:
Net Debt and Net Capitalization Reconciliation
June 30,June 30,March 31,
(in thousands)202620252026
Add: Notes payable and overdrafts$567,011 $621,275 $287,564 
Add: Long-term obligations616,869 618,057 616,727 
Add: Current portion of long-term obligations— — — 
Total Debt 1,183,880 1,239,332 904,291 
Add: Customer advances and deposits3,531 4,557 3,376 
Less: Cash and cash equivalents173,593 178,435 62,178 
Net Debt (non-GAAP)$1,013,818 $1,065,454 $845,489 
Add: Total Universal Corporation shareholders' equity1,388,829 1,458,917 1,415,400 
Net Capitalization (non-GAAP)$2,402,647 $2,524,371 $2,260,889 
Net Debt/Net Capitalization (non-GAAP)42 %42 %37 %
Liquidity and Capital Resources
Overview
Our liquidity and operating capital resource requirements are predominantly short term in nature and primarily relate to working capital for tobacco crop purchases. Working capital needs are seasonal within each geographic region. The geographic dispersion and the timing of working capital needs permit us to predict our general level of cash requirements, although tobacco crop sizes, prices paid to farmers, shipment and delivery timing, and currency fluctuations affect requirements each year. Peak working capital requirements are generally reached during the first and second fiscal quarters. Each geographic area follows a cycle of buying, processing, and shipping tobacco to customers, and in many regions, we also provide agricultural materials to farmers during the growing season. The timing of the elements of each cycle is influenced by such factors as local weather conditions and individual customer shipping requirements, which may change the level or the duration of crop financing. Despite a predominance of short-term needs, we maintain a portion of our total debt as long-term to reduce liquidity risk. We also periodically have large cash balances that we utilize to meet our working capital requirements.

Our first fiscal quarter is typically a period of significant working capital investment in Africa and South America as farmers deliver tobacco crops. For the quarter ended June 30, 2026, working capital investment remained significant, but was lower than in the quarter ended June 30, 2025, primarily due to an oversupply of tobacco, particularly flue-cured and burley tobacco, in the global market. As a result of these market conditions, green tobacco purchases were slower and green tobacco prices were lower than in the prior-year quarter, reducing our working capital requirements. We funded these requirements through a combination of cash on hand, short-term borrowings, customer advances, accounts receivable factoring, and operating cash flows.

Operating Activities
Net cash used by our operations was $117.1 million during the quarter ended June 30, 2026. That amount was $88.0 million lower than during the same period in fiscal year 2026, primarily on lower working capital requirements. Tobacco inventory levels at June 30, 2026, were down $54.2 million, compared to June 30, 2025 levels, on slower green tobacco purchases and lower green tobacco prices. We generally do not purchase material quantities of tobacco on a speculative basis, and we target committed inventory levels of 80% or more of total tobacco inventory. Our level of committed inventory percentages is influenced by timing of farmer deliveries of new crops, as well as the receipt of customer orders. In addition, when we contract directly with tobacco farmers, we are often obligated to buy all stalk positions, which may contain less marketable leaf styles. As of June 30, 2026, our uncommitted tobacco inventories were $275.1 million, or about 24% of total tobacco inventory, compared to $222.3 million, or about 27% of our tobacco inventory as of March 31, 2026, and $134.7 million, or about 11% of our tobacco inventory as of June 30, 2025. Uncommitted tobacco levels as a percentage of total tobacco inventory came down from March 31, 2026 levels in the quarter ended June 30, 2026, but remained elevated due to delayed customer purchase commitments. We expect our uncommitted tobacco inventory levels to be within our range of 20% or less of total tobacco inventory during fiscal year 2027.

28


Our balance sheet accounts reflected seasonal patterns in the quarter ended June 30, 2026, on deliveries of tobacco crops by farmers in Africa and South America. Accounts receivable decreased by $215.8 million from March 31, 2026 levels on collections on receivables, partially offset by tobacco crop shipments. Advances to suppliers were $102.9 million at June 30, 2026, a reduction of $74.3 million from March 31, 2026, as tobacco crops were delivered in payment on some of those balances, net of new balances for upcoming tobacco crops. Accounts receivable--unconsolidated affiliates increased by $92.2 million from March 31, 2026 levels, on tobacco crop purchases. Notes payable and overdrafts were up $279.4 million from March 31, 2026 levels on seasonal working capital needs.

Accounts receivable were $76.1 million lower in the quarter ended June 30, 2026, compared to the quarter ended June 30, 2025, on lower sales of carryover crop tobacco. Advances to suppliers were $23.7 million higher and accounts payable were $28.8 million lower at June 30, 2026, compared to June 30, 2025, largely on slower purchases of green tobacco. Accounts receivable--unconsolidated affiliates were $23.2 million lower as of June 30, 2026, compared to the same period in the prior fiscal year, on the timing of tobacco shipments. Notes payable and overdrafts were down $54.3 million as of June 30, 2026, compared to June 30, 2025, due to lower working capital requirements.

Investing Activities
Our capital allocation strategy focuses on four strategic priorities: strengthening and investing for growth in our leaf tobacco business; increasing our strong dividend; exploring growth opportunities for our ingredients business; and returning excess capital to our shareholders. In deciding where to invest capital resources, we look for opportunities where we believe we can earn an adequate return as well as leverage our assets and expertise or enhance our farmer base. Our capital expenditures are generally limited to those that add value, replace or maintain equipment, increase efficiency, or position us for future growth. During the quarters ended June 30, 2026 and 2025, we invested approximately $15.9 million and $12.1 million, respectively, in our property, plant and equipment. Depreciation expense was approximately $11.0 million for each of the quarters ended June 30, 2026 and 2025. Typically, our capital expenditures for maintenance projects are less than $30 million per fiscal year. In addition, from time to time, we undertake projects that require capital expenditures when we identify opportunities to improve efficiencies, invest in sustainability projects, add value for our customers, and position ourselves for future growth. We currently expect to spend approximately $55 to $65 million over the next twelve months on capital projects for maintenance of our facilities and other investments to grow and improve our businesses.

Our Board of Directors approved our current share repurchase program in November 2024. The program authorizes the purchase of up to $100 million of our common stock through November 15, 2026. Under the current authorization, we may purchase shares from time to time on the open market or in privately negotiated transactions at prices not exceeding prevailing market rates. Repurchases of shares under the repurchase program may vary based on management discretion, as well as changes in cash flow generation and availability. During the three months ended June 30, 2026, we purchased 51,741 shares of common stock at an aggregate cost of $2.7 million (average price per share $53.06). As of June 30, 2026, our available authorization under our current share repurchase program was $97.3 million.

Financing Activities

At June 30, 2026, we had $1.2 billion in total debt outstanding, a decrease of $55.5 million compared to June 30, 2025. We consider the sum of notes payable and overdrafts, long-term debt (including any current portion), and customer advances and deposits, less cash, cash equivalents, and short-term investments on our balance sheet to be our net debt. We also consider our net debt plus shareholders' equity to be our net capitalization. Net debt decreased by $51.6 million to $1.0 billion at June 30, 2026, compared to June 30, 2025. Net debt as a percentage of net capitalization was 42% at June 30, 2026, flat with 42% at June 30, 2025, and up from 37% at March 31, 2026.

As of June 30, 2026, we had $174 million in cash and cash equivalents, $635 million available under our committed revolving credit facility that will mature in December 2030, and we, together with our consolidated affiliates, had approximately $279 million in available, uncommitted credit lines. The financial covenants under our committed revolving credit facility require us to maintain certain levels of tangible net worth and observe restrictions on debt levels. Based on our June 30, 2026 financial statements, we were in compliance with all financial covenants of our debt agreements as of June 30, 2026. We have no long-term debt maturing until fiscal year 2031.

Our seasonal working capital requirements for our tobacco business typically increase significantly between March and September and decline after mid-fiscal year. Available capital resources from our cash balances, committed revolving credit facility, and uncommitted credit lines are expected to exceed our normal working capital needs and currently anticipated capital expenditure requirements over the next twelve months and beyond.

29


Derivatives
From time to time, we use interest rate swap agreements to manage our exposure to changes in interest rates. At June 30, 2026, the fair value of our outstanding interest rate swap agreements was an asset of about $5.0 million, and the notional amount swapped was $310 million. We entered into these agreements to eliminate the variability of cash flows in the interest payments on a portion of our variable-rate term loans. Under the swap agreements we receive variable rate interest and pay fixed rate interest. The swaps are accounted for as cash flow hedges.

We also use derivative instruments from time to time to hedge certain foreign currency exposures, primarily related to forecasted purchases of tobacco, related processing costs, and crop input sales, as well as our net monetary balance sheet exposures in local currency. We generally account for our hedges of forecasted tobacco purchases as cash flow hedges. As of June 30, 2026, the fair value of our open hedges for forecasted tobacco purchases and crop inputs was a net liability of approximately $3.0 million. We had forward contracts outstanding that were not designated as hedges, and the fair value of those contracts was a net liability of approximately $1.1 million as of June 30, 2026.

Critical Accounting Estimates
A summary of our critical accounting policies is included in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our 2025 Form 10-K. Our critical accounting policies have not changed from those reported in the 2026 Form 10-K.
30


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There have been no material changes to the Company's market risk during the three months ended June 30, 2026. For a discussion of the Company's exposure to market risk, refer to the Company's market risk disclosures set forth in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" of the 2026 Form 10-K.
ITEM 4. CONTROLS AND PROCEDURES
The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports filed by the Company under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. The Company’s Chief Executive Officer and Chief Financial Officer evaluated, with the participation of the Company’s management, the effectiveness of the Company’s disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)), as of the end of the period covered by this Form 10-Q. Based on this evaluation, the Company’s management, including its Chief Executive Officer and Chief Financial Officer, concluded that the Company’s disclosure controls and procedures were effective.
There were no changes in the Company’s internal control over financial reporting that occurred during the Company’s fiscal quarter ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
31


PART II. OTHER INFORMATION
ITEM 1.   LEGAL PROCEEDINGS
Other Legal Matters
Some of our subsidiaries are involved in litigation or legal matters incidental to their business activities. While the outcome of these matters cannot be predicted with certainty, we are vigorously defending them and do not currently expect that any of them will have a material adverse effect on our business or financial position. However, should one or more of these matters be resolved in a manner adverse to our current expectation, the effect on our results of operations for a particular fiscal reporting period could be material.
ITEM 1A. RISK FACTORS
There are no material changes to the risk factors previously disclosed in our 2026 Form 10-K. In evaluating our risks, readers should carefully consider the risk factors discussed in our 2026 Form 10-K, which could materially affect our business, financial condition or operating results, in addition to the other information set forth in this Form 10-Q and in our other filings with the SEC.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY
    The following table sets forth repurchased shares of our common stock during the three-month period ended June 30, 2026:
Period (1)
Total Number of Shares Repurchased
Average Price Paid Per Share (2)
Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs (3)
Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (3)
April 1-30, 2026— $— — $100,000,000 
May 1-31, 2026— — — 100,000,000 
June 1-30, 202651,741 53.06 51,741 97,254,583 
Total51,741 $53.06 51,741 $97,254,583 
(1)Repurchases are based on the date the shares were traded. This presentation differs from the consolidated statement of cash flows, where the cost of share repurchases is based on the date the transactions were settled.
(2)Amounts listed for average price paid per share include broker commissions paid in the transactions.
(3)On November 7, 2024, the Company's Board of Directors, approved a stock repurchase program for the purchase of up to $100 million in common stock in open market or privately negotiated transactions through November 15, 2026, subject to market conditions and other factors. The program had $97 million of remaining capacity for repurchases of common stock at June 30, 2026.
Our current dividend policy anticipates the payment of quarterly dividends in the future. However, the declaration and payment of dividends to holders of common stock is at the discretion of the Board of Directors and will be dependent upon our future earnings, financial condition, and capital requirements. Under certain provisions of our credit facilities, we must meet financial covenants relating to minimum tangible net worth and maximum levels of debt. If we were not in compliance with them, these financial covenants could restrict our ability to pay dividends. We were in compliance with all such covenants at June 30, 2026.

ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
During the three months ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933, as amended).
32


 ITEM 6.   EXHIBITS
31.1
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350.*
32.2
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350.*
101Interactive Data File (submitted electronically herewith).*
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH XBRL Taxonomy Extension Schema Document 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF XBRL Taxonomy Extension Definition Linkbase Document 101.LAB XBRL Taxonomy Extension Label Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section and shall not be part of any registration or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
    __________
*Filed herewith

33


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
UNIVERSAL CORPORATION
(Registrant)
Date:August 5, 2026/s/ Steven S. Diel
Steven S. Diel, Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
Date:August 5, 2026/s/ Scott J. Bleicher
Scott J. Bleicher, Vice President and Controller
(Principal Accounting Officer)


34